Department of Biochemistry and Molecular Biology, University of Athens, Greece.
Biol Chem. 2010 Apr;391(4):467-74. doi: 10.1515/BC.2010.026.
Kallikrein-related peptidases (KLKs), including KLK5, have been proposed as promising biomarkers for prostate cancer diagnosis and prognosis. In the present study, we report that distinct augmentations (up to 6.4-fold) of KLK5 mRNA expressional levels, calculated via quantitative real-time PCR, occur after treatment of DU145 cells with appropriate concentrations, determined by the MTT method, of docetaxel and mitoxantrone. Our data reveal the endogenous need of prostate cancer cells for modified KLK5 expression to cope with the administration of chemotherapeutic drugs. Furthermore, it is proposed that the expression profile of KLK5 could serve as a putative biomarker for monitoring the treatment response in hormone refractory prostate cancer patients.
激肽释放酶相关肽酶（KLKs），包括 KLK5，已被提议作为前列腺癌诊断和预后的有前途的生物标志物。在本研究中，我们报告说，通过定量实时 PCR 计算，在用 MTT 法确定的适当浓度的多西他赛和米托蒽醌处理 DU145 细胞后，KLK5 mRNA 表达水平会出现明显的增加（高达 6.4 倍）。我们的数据揭示了前列腺癌细胞对修饰的 KLK5 表达的内在需求，以应对化疗药物的治疗。此外，提出 KLK5 的表达谱可以作为监测激素难治性前列腺癌患者治疗反应的潜在生物标志物。
